Kancera develops drugs against inflammatory diseases and cancer.

Demonstrated effect on the Fractalkine system in humans has strengthened the basis for continued clinical development in a Phase II study.

Kancera AB conducts research and development in laboratories at Karolinska Institutet Science Park in Stockholm and employs about 15 people.The share is traded on NASDAQ First North Premier.

Kancera’s foundations were born of  research carried out by Sweden’s Karolinska Institute, and of the industrial and drug discovery traditions established by AstraZeneca, Pharmacia (now Pfizer), and Biovitrum (now Swedish Orphan Biovitrum).

MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB.